[1]
|
Babapulle, M.N., Joseph, L., Bélisle, P., Brophy, J.M. and Eisenberg, M.J. (2004) A Hierarchical Bayesian Meta-Analysis of Randomised Clinical Trials of Drug-Eluting Stents. Lancet, 364, 583-591.
http://dx.doi.org/10.1016/S0140-6736(04)16850-5
|
[2]
|
Serruys, P.W., Morice, M.C., Kappetein, A.P., Colombo, A., Holmes, D.R., Mack, M.J., Stahle, E., Feldman, T.E., van den Brand, M., Bass, E.J., Van Dyck, N., Leadley, K., Dawkins, K.D. and Mohr, F.W. (2009) Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease. New England Journal of Medicine, 360, 961-972. http://dx.doi.org/10.1056/NEJMoa0804626
|
[3]
|
Farkouh, M.E., Domanski, M., Sleeper, L.A., Siami, F.S., Dangas, G., Mack, M., Yang, M., Cohen, D.J., Rosenberg, Y., Solomon, S.D., Desai, A.S., Gersh, B.J., Magnuson, E.A., Lansky, A., Boineau, R., Weinberger, J., Ramanathan, K., Sousa, J.E., Rankin, J., Bhargava, B., Buse, J., Hueb, W., Smith, C.R., Muratov, V., Bansilal, S., King, 3rd, S., Bertrand, M. and Fuster, V. (2012) Strategies for Multivessel Revascularization in Patients with Diabetes. New England Journal of Medicine, 367, 2375-2384. http://dx.doi.org/10.1056/NEJMoa1211585
|
[4]
|
Joner, M., Finn, A.V., Farb, A., Mont, E.K., Kolodgie, F.D., Ladich, E., Kutys, R., Skorija, K., Gold, H.K. and Virmani, R. (2006) Pathology of Drug-Eluting Stents in Humans: Delayed Healing and Late Thrombotic Risk. Journal of the American College of Cardiology, 48, 193-202. http://dx.doi.org/10.1016/j.jacc.2006.03.042
|
[5]
|
Nakano, M., Otsuka, F., Yahagi, K., Sakakura, K., Kutys, R., Ladich, E.R., Finn, A.V., Kolodgie, F.D. and Virmani, R. (2013). Human Autopsy Study of Drug-Eluting Stents Restenosis: Histomorphological Predictors and Neointimal Characteristics. European Heart Journal, 34, 3304-3313. http://dx.doi.org/10.1093/eurheartj/eht241
|
[6]
|
Hofma, S.H., van der Giessen, W.J., van Dalen, B.M., Lemos, P.A., McFadden, E.P., Sianos, G., Ligthart, J.M., van Essen, D., de Feyter, P.J. and Serruys, P.W. (2006) Indication of Long-Term Endothelial Dysfunction after Sirolimus-Eluting Stent Implantation. European Heart Journal, 27, 166-170. http://dx.doi.org/10.1093/eurheartj/ehi571
|
[7]
|
Shin, D.I., Kim, P.J., Seung, K.B., Kim, D.B., Kim, M.J., Chang, K., Lim, S.M., Jeon, D.S., Chung, W.S., Baek, S.H. and Lee, M.Y. (2007) Drug-Eluting Stent Implantation Could Be Associated with Long-Term Coronary Endothelial Dysfunction. International Heart Journal, 48, 553-567. http://dx.doi.org/10.1536/ihj.48.553
|
[8]
|
Fuke, S., Maekawa, K., Kawamoto, K., Saito, H., Sato, T., Hioka, T. and Ohe, T. (2007) Impaired Endothelial Vasomotor Function after Sirolimus-Eluting Stent Implantation. Circulation Journal, 71, 220-225.
http://dx.doi.org/10.1253/circj.71.220
|
[9]
|
Hamilos, M.I., Ostojic, M., Beleslin, B., Sagic, D., Mangovski, L., Stojkovic, S., Nedeljkovic, M., Orlic, D., Milosavljevic, B., Topic, D., Karanovic, N., Wijns, W., NOBORI CORE Investigators (2008) Differential Effects of Drug-Eluting Stents on Local Endothelium-Dependent Coronary Vasomotion. Journal of the American College of Cardiology, 51, 2123-2129. http://dx.doi.org/10.1016/j.jacc.2007.12.059
|
[10]
|
Sousa, J.E., Serruys, P.W. and Costa, M.A. (2003) New Frontiers in Cardiology: Drug-Eluting Stents: Part II. Circulation, 107, 2383-2389. http://dx.doi.org/10.1161/01.CIR.0000069331.67148.2F
|
[11]
|
Carter, A.J., Laird, J.R., Farb, A., Kufs, W., Wortham, D.C. and Virmani, R. (1994) Morphologic Characteristics of Lesion Formation and Time Course of Smooth Muscle Cell Proliferation in a Porcine Proliferative Restenosis Model. Journal of the American College of Cardiology, 24, 1398-1405. http://dx.doi.org/10.1016/0735-1097(94)90126-0
|
[12]
|
Kornowski, R., Hong, M.K., Tio, F.O., Bramwell, O., Wu, H. and Leon, M.B. (1998) In-Stent Restenosis: Contributions of Inflammatory Responses and Arterial Injury to Neointimal Hyperplasia. Journal of the American College of Cardiology, 31, 224-230. http://dx.doi.org/10.1016/S0735-1097(97)00450-6
|
[13]
|
Vane, J.R. and Botting, R.M. (1995) Pharmacodynamic Profile of Prostacyclin. American Journal of Cardiology, 75, 3A-10A. http://dx.doi.org/10.1016/S0002-9149(99)80377-4
|
[14]
|
Zucker, T.P., Bönisch, D., Hasse, A., Grosser, T., Weber, A.A. and Schrör, K. (1998) Tolerance Development to Antimitogenic Actions of Prostacyclin but Not of Prostaglandin E1 in Coronary Artery Smooth Muscle Cells. European Journal of Pharmacology, 345, 213-220. http://dx.doi.org/10.1016/S0014-2999(98)00022-3
|
[15]
|
Voisard, R., Stemberger, A., Baur, R., Herter, T., Hähnel, I., Resch, A., Seliger, C., Hemmer, W., Hannekum, A., Hombach, V. and Alt, E. (2005) Triple-Coated Stents (Hirudin/Iloprost/Paclitaxel): An in Vitro Approach for Characterizing the Antiproliferative Potential of Each Individual Compound. International Journal of Cardiology, 102, 425-433. http://dx.doi.org/10.1016/j.ijcard.2004.05.059
|
[16]
|
Hata, A.N. and Breyer, R.M. (2004) Pharmacology and Signaling of Prostaglandin Receptors: Multiple Roles in Inflammation and Immune Modulation. Pharmacology and Therapeutics, 103, 147-166.
http://dx.doi.org/10.1016/j.pharmthera.2004.06.003
|
[17]
|
Della Bella, S., Molteni, M., Mocellin, C., Fumagalli, S., Bonara, P. and Scorza, R. (2001) Novel Mode of Action of Iloprost: In Vitro Down-Regulation of Endothelial Cell Adhesion Molecules. Prostaglandins and Other Lipid Mediators, 65, 73-83. http://dx.doi.org/10.1016/S0090-6980(01)00131-9
|
[18]
|
Alt, E., Haehnel, I., Beilharz, C., Prietzel, K., Preter, D., Stemberger, A., Fliedner, T., Erhardt, W. and Sch?mig, A. (2000) Inhibition of Neointima Formation after Experimental Coronary Artery Stenting: A New Biodegradable Stent Coating Releasing Hirudin and the Prostacyclin Analogue Iloprost. Circulation, 101, 1453-1458.
http://dx.doi.org/10.1161/01.CIR.101.12.1453
|
[19]
|
McCormick, C., Jones, R.L., Kennedy, S. and Wadsworth, R.M. (2010) Activation of Prostanoid EP Receptors by Prostacyclin Analogues in Rabbit Iliac Artery: Implications for Anti-Restenotic Potential. European Journal of Pharmacology, 641, 160-167. http://dx.doi.org/10.1016/j.ejphar.2010.04.035
|
[20]
|
Abramovitz, M., Adam, M., Boie, Y., Carrière, M., Denis, D., Godbout, C., Lamontagne, S., Rochette, C., Sawyer, N., Tremblay, N.M., Belley, M., Gallant, M., Dufresne, C., Gareau, Y., Ruel, R., Juteau, H., Labelle, M., Ouimet, N. and Metters, K.M. (2000) The Utilization of Recombinant Prostanoid Receptors to Determine the Affinities and Selectivities of Prostaglandins and Related Analogs. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids, 1483, 285-293. http://dx.doi.org/10.1016/s1388-1981(99)00164-x
|
[21]
|
Coats, P., Kennedy, S., Pyne, S., Wainwright, C.L. and Wadsworth, R.M. (2008) Inhibition of Non-Ras Protein Farnesylation Reduces In-Stent Restenosis. Atherosclerosis, 197, 515-523.
http://dx.doi.org/10.1016/j.atherosclerosis.2007.06.007
|
[22]
|
Malik, N., Gunn, J., Holt, C.M., Shepherd, L., Francis, S.E., Newman, C.M., Crossman, D.C. and Cumberland, D.C. (1998) Intravascular Stents: A New Technique for Tissue Processing for Histology, Immunohistochemistry, and Transmission Electron Microscopy. Heart, 80, 509-516. http://dx.doi.org/10.1136/hrt.80.5.509
|
[23]
|
Gunn, J., Arnold, N., Chan, K.H., Shepherd, L., Cumberland, D.C. and Crossman, D.C. (2002) Coronary Artery Stretch versus Deep Injury in the Development of In-Stent Neointima. Heart, 88, 401-405.
http://dx.doi.org/10.1136/heart.88.4.401
|
[24]
|
Levitt, M.A., Dryjski, M., Tluczek, J. and Bjornsson, T.D. (1991) Evaluation of a Prostacyclin Analog, Iloprost, and a Thromboxane A2 Receptor Antagonist, Daltroban, in Experimental Intimal Hyperplasia. Prostaglandins, 41, 1-6.
http://dx.doi.org/10.1016/0090-6980(91)90099-2
|
[25]
|
Banning, A., Brewer, L., Wendt, M., Groves, P.H., Cheadle, H., Penny, W.J. and Crawford, N. (1997) Local Delivery of Platelets with Encapsulated Iloprost to Balloon Injured Pig Carotid Arteries: Effect on Platelet Deposition and Neointima Formation. Thrombosis and Haemostasis, 77, 190-196.
|
[26]
|
Isogaya, M., Yamada, N., Koike, H., Ueno, Y., Kumagai, H., Ochi, Y., Okazaki, S. and Nishio, S. (1995) Inhibition of Restenosis by Beraprost Sodium (a Prostaglandin I2 Analogue) in the Atherosclerotic Rabbit Artery after Angioplasty. Journal of Cardiovascular Pharmacology, 25, 947-952. http://dx.doi.org/10.1097/00005344-199506000-00013
|
[27]
|
Schwartz, R.S., Chronos, N.A. and Virmani, R. (2004) Preclinical Restenosis Models and Drug-Eluting Stents: Still Important, Still Much to Learn. Journal of the American College of Cardiology, 44, 1373-1385.
http://dx.doi.org/10.1016/j.jacc.2004.04.060
|
[28]
|
Blindt, R., Bosserhoff, A.K., vom Dahl, J., Hanrath, P., Schror, K., Hohlfeld, T. and Meyer-Kirchrath, J. (2002) Activation of IP and EP3 Receptors Alters cAMP-Dependent Cell Migration. European Journal of Pharmacology, 444, 31-37. http://dx.doi.org/10.1016/S0014-2999(02)01607-2
|
[29]
|
Murata, T., Ushikubi, F., Matsuoka, T., Hirata, M., Yamasaki, A., Sugimoto, Y., Ichikawa, A., Aze, Y., Tanaka, T., Yoshida, N., Ueno, A., Oh-ishi, S. and Narumiya, S. (1997) Altered Pain Perception and Inflammatory Response in Mice Lacking Prostacyclin Receptor. Nature, 388, 678-682. http://dx.doi.org/10.1038/41780
|
[30]
|
Fetalvero, K.M., Martin, K.A. and Hwa, J. (2007) Cardioprotective Prostacyclin Signaling in Vascular Smooth Muscle. Prostaglandins and Other Lipid Mediators, 82, 109-118. http://dx.doi.org/10.1016/j.prostaglandins.2006.05.011
|
[31]
|
Sirois, M.G., Simons, M., Kuter, D.J., Rosenberg, R.D. and Edelman, E.R. (1997) Rat Arterial Wall Retains Myointimal Hyperplastic Potential Long after Arterial Injury. Circulation, 96, 1291-1298.
http://dx.doi.org/10.1161/01.CIR.96.4.1291
|
[32]
|
Banai, S., Gertz, S.D., Gavish, L., Chorny, M., Perez, L.S., Lazarovichi, G., Ianculuvich, M., Hoffmann, M., Orlowski, M., Golomb, G. and Levitzki, A. (2004) Tyrphostin AGL-2043 Eluting Stent Reduces Neointima Formation in Porcine Coronary Arteries. Cardiovascular Research, 64, 165-171. http://dx.doi.org/10.1016/j.cardiores.2004.06.013
|
[33]
|
Tamai, H., Igaki, K., Kyo, E., Kosuga, K., Kawashima, A., Matsui, S., Komori, H., Tsuji, T., Motohara, S. and Uehata, H. (2000) Initial and 6-Month Results of Biodegradable Poly-l-Lactic Acid Coronary Stents in Humans. Circulation, 102, 399-404. http://dx.doi.org/10.1161/01.CIR.102.4.399
|
[34]
|
Lincoff, A.M., Furst, J.G., Ellis, S.G., Tuch, R.J. and Topol, E.J. (1997) Sustained Local Delivery of Dexamethasone by a Novel Intravascular Eluting Stent to Prevent Restenosis in the Porcine Coronary Injury Model. Journal of the American College of Cardiology, 29, 808-816. http://dx.doi.org/10.1016/S0735-1097(96)00584-0
|
[35]
|
Mani, G., Feldman, M.D., Patel, D. and Agrawal, C.M. (2007) Coronary Stents: A Materials Perspective. Biomaterials, 28, 1689-1710. http://dx.doi.org/10.1016/j.biomaterials.2006.11.042
|
[36]
|
van der Giessen, W.J., Lincoff, A.M., Schwartz, R.S., van Beusekom, H.M., Serruys, P.W., Holmes Jr., D.R. Ellis, S.G. and Topol, E.J. (1996) Marked Inflammatory Sequelae to Implantation of Biodegradable and Nonbiodegradable Polymers in Porcine Coronary Arteries. Circulation, 94, 1690-1697. http://dx.doi.org/10.1161/01.CIR.94.7.1690
|
[37]
|
Moses, J.W., Leon, M.B., Popma, J.J., Fitzgerald, P.J., Holmes, D.R., O’Shaughnessy, C., Caputo, R.P., Kereiakes, D.J., Williams, D.O., Teirstein, P.S., Jaeger, J.L. and Kuntz, R.E. (2003) Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary Artery. The New England Journal of Medicine, 349, 1315-1323.
http://dx.doi.org/10.1056/NEJMoa035071
|